Bob
Senior Member
- Messages
- 16,455
- Location
- England (south coast)
Chronic fatigue syndrome: the current status and future potentials of emerging biomarkers
David B. Fischer, Arsani H. William, Adam C. Strauss, Elizabeth R. Unger, Leonard A. Jason, Gailen D. Marshall, Jordan D. Dimitrakoff
Fatigue: Biomedicine, Health & Behavior
Vol. 2, Iss. 2, 2014
http://dx.doi.org/10.1080/21641846.2014.906066
David B. Fischer, Arsani H. William, Adam C. Strauss, Elizabeth R. Unger, Leonard A. Jason, Gailen D. Marshall, Jordan D. Dimitrakoff
Fatigue: Biomedicine, Health & Behavior
Vol. 2, Iss. 2, 2014
http://dx.doi.org/10.1080/21641846.2014.906066
Abstract
Background: Chronic fatigue syndrome (CFS) remains an incompletely characterized illness, in part due to controversy regarding its definition, biological basis, and diagnosis.
Purpose: Biomarkers are objective measures that may lead to improvements in our understanding of CFS by providing a more coherent and consistent approach to study, diagnosis, and treatment of the illness. Such metrics may allow us to distinguish between CFS subtypes – each defined by characteristic biomarkers – currently conflated under the single, heterogeneous condition of CFS. These delineations, in turn, may guide more granular, focused, and targeted treatment strategies based on more precise characterizations of the illness.
Methods: Here, we review potential CFS biomarkers related to neurological and immunological components of the illness.
Results, Conclusions: We discuss how these biomarkers may be used to move the field of CFS forward, emphasizing clinical utility and potential routes of future research.